TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06670521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 50 mg methylprednisolone IV every 6 hours for 4 doses to reduce laryngeal edema

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline placebo IV every 6 hours for 4 doses
Study: NCT05492994

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Pulmonary function test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)
Description: Pulmonary function test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chest Computer Tomography
Description: Chest Computer Tomography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood biomarker analysis
Description: Blood biomarker analysis
Study: NCT05898269

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End-expiratory and end-inspiratory occlusion test (EI OCC)
Description: End-inspiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause. The evaluator is calculated as the sum of the relative change in cardiac index observed during the end-expiratory pause and that of the end-inspiratory pause. Hence, for this test, the evaluator will be coupled with that of intervention 2 (end-expiratory occlusion test).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End-expiratory and end-inspiratory occlusion test (EI OCC)
Description: End-inspiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause. The evaluator is calculated as the sum of the relative change in cardiac index observed during the end-expiratory pause and that of the end-inspiratory pause. Hence, for this test, the evaluator will be coupled with that of intervention 2 (end-expiratory occlusion test).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End-expiratory and end-inspiratory occlusion test (EI OCC)
Description: End-inspiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause. The evaluator is calculated as the sum of the relative change in cardiac index observed during the end-expiratory pause and that of the end-inspiratory pause. Hence, for this test, the evaluator will be coupled with that of intervention 2 (end-expiratory occlusion test).
Study: NCT06671665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium supplementation
Description: Patients in both groups received calcium supplementation in the form of tablets that contain 665 mg calcium citrate. Citrate is easily assimilated and metabolized which provides the maximum benefit of the formula. Dosage: one tablet daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium supplementation
Description: Patients in both groups received calcium supplementation in the form of tablets that contain 665 mg calcium citrate. Citrate is easily assimilated and metabolized which provides the maximum benefit of the formula. Dosage: one tablet daily.
Study: NCT06671665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy treatment will be in the form of craniosacral techniques and visceral manipulation techniques for 8 sessions in 12 weeks. Sessions will be divided into one session per week for the first 4 weeks then one session every two week for the next 8 weeks. Each session lasts for 45 minutes.
Study: NCT05681442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous pivotal βL-AB
Description: continuous pivotal βL-AB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous pivotal βL-AB
Description: continuous pivotal βL-AB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intermittent pivotal βL-AB
Description: intermittent pivotal βL-AB (IID = control group)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intermittent pivotal βL-AB
Description: intermittent pivotal βL-AB (IID = control group)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG infusion most 1 dose
Description: AG infusion most 1 dose (AMT group )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG infusion most 1 dose
Description: AG infusion most 1 dose (AMT group )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG infusion for 5 days
Description: AG infusion for 5 days (ACT Group)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG infusion for 5 days
Description: AG infusion for 5 days (ACT Group)
Study: NCT06393998

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breathing with CO2 during daytime and night at high altitude
Description: Subjects wear the mask connecting to low dose CO2 supplied by a novel device during daytime and sleep dependent on the randomization once arriving high altitude.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sleep and doing exercise test under inhalation of air
Description: Subjects wear the mask connecting to air supplied by the novel device during daytime and sleep dependent on the randomization once arriving high altitude.
Study: NCT05658341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADA
Description: The 12-weeks program will include one-hour in adapted physical activity (APA), and a discussion on relaxation techniques and the undertaking of deep breathing exercises (making them APA+ sessions). A series of minute for nutrition short information sheets will be distributed at the end of each session.~Two workshops on living better after breast cancer will also be offered: one on general mobility and the other on daily nutrition.~Moreover, women will be asked to set personal challenges as a method of motivational reinforcement, and will also be called for motivational check-ins at least 3 times. Follow-up calls will allow for further individualization, motivation, and the reception of participants' concerns or remarks.~Further, participants in the intervention group will have access to a dedicated internet space containing several documents and videos on topics of concern to patients during the post-treatment phase.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the control group will be offered weekly APA sessions for 12 weeks, these sessions are based on current practices within the Siel Bleu organization. Sessions' content is adapted to people who have been treated for (all types) cancer and are based on current recommendations.~These sessions are commonly organized by Siel Bleu in hospitals, community groups or local committees of the national league against cancer organization.
Study: NCT06463457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Androgen receptor antagonist, tablet taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Androgen receptor antagonist, tablet taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Gonadotropin-releasing hormone (GnRH) receptor antagonist, tablet taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Gonadotropin-releasing hormone (GnRH) receptor antagonist, tablet taken orally per protocol.
Study: NCT06159647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinking guidelines
Description: Participants will view messages about guidelines for alcohol consumption.
Study: NCT05843448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1/IDO Peptide Vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04927364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Transcranial Magnetic Stimulation (dTMS) H7 coil
Description: The study will utilize the H7 coil to administer Deep Transcranial Magnetic Stimulation (dTMS) to the dorsal anterior cingulate cortex (dACC), a core salience network node.
Study: NCT04802954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video acquisition
Description: One to three video acquisitions of 10 seconds will be carried out via the intercostal route. Data acquisition will be standardized according to a mandatory protocol and previously recorded in each ultrasound machine (cross shots, harmonic, filter, depth, focal length, mechanical index, etc.).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video acquisition
Description: One to three video acquisitions of 10 seconds will be carried out via the intercostal route. Data acquisition will be standardized according to a mandatory protocol and previously recorded in each ultrasound machine (cross shots, harmonic, filter, depth, focal length, mechanical index, etc.).
Study: NCT06542588

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody)
Description: Short course radiotherapy sequential HLX07, Serplulimab and chemotherapy
Study: NCT06195332

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open TAR
Description: Participants will undergo open TAR repair according to the assigned treatment arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic TAR
Description: Participants will undergo endoscopic TAR repair according to the assigned treatment arm.
Study: NCT05780723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment group: Rectal instillation of QHQYP
Description: QHQYP is decocted in water, with a dose of 100ml each time, and rectal drip before going to bed, once a night, for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group: Mesalazine enema treatment
Description: Mesalazine enema, 4g/tube, 1 tube each time, enema before bed, once a night, a total of 8 weeks of continuous treatment.
Study: NCT04658342

Intervention type: DIAGNOSTIC_TEST
Intervention: Videofluoroscopic imaging (VFSS) with high-resolution manometry (HRM)
Description: The Videofluoroscopic Imaging (VFSS) is done by inserting a small catheter into the nose and down the throat. The catheter is approximately .4 millimeters in diameter. A trained speech-language pathologist will insert the catheter after applying numbing medicine, or topical anesthetic, inside the nose.~The high-resolution manometry (HRM) is a swallowing pressure test done at the same time as the VFSS. The HRM will measure how strong the throat muscle squeeze the liquids and foods that a person swallows.~The VFSS and HRM will occur about one month after surgery and three months after the completion of the radiation treatment.
Study: NCT05971251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine and Acalabrutinib
Description: Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine and Acalabrutinib
Description: Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine and Acalabrutinib
Description: Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine and Acalabrutinib
Description: Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib
Study: NCT05109494

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fractionated
Description: 50 Gy in 25 fractions will be prescribed to cover 95% of the planning tumor volume (PTV). More than 99% of the PTV should receive \> 97% of the prescribed dose. For dose homogeneity, no more than 20% of the PTV will receive ≥ 110% prescription dose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated
Description: 27.5 Gy in 5 fractions will be prescribed to cover 95% of the PTV. More than 99% of the PTV should receive \> 97% of the prescribed dose
Study: NCT06056219

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: 30 minutes' mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise of less-affected upper extremity using a mirror box

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality-based mirror therapy with rhythmic skill training
Description: 30 minutes' virtual reality-based mirror therapy with rhythmic skill training included musical exercises involving virtual drums playing with less-affected upper extremity, and synchronized virtual drums playing and singing activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task-oriented training
Description: 20 minutes' motor training targeted to goals that are relevant to the functional needs of the patient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented training
Description: 20 minutes' motor training targeted to goals that are relevant to the functional needs of the patient
Study: NCT04974099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RoadMAB
Description: The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precision dosing with a dashboard
Description: The trial is testing whether precision dosing can more reliably achieve the targeted trough concentrations compared to standard dosing
Study: NCT05577702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an intravenous infusion
Study: NCT06671366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external and internal shoulder rotation using a Cybex dynamometer
Description: Measurement of the reproducibility, in this precise evaluation position, of the results obtained between the different tests carried out 30 minutes apart, and thus the reliability of each measurement in this test.~measures :~* Concentric internal rotation 60degrees/sec~* Concentric external rotation 60 degrees/sec~* Concentric internal rotation 180 degrees/sec~* Concentric external rotation 180 degrees/sec~* Eccentric internal rotation 60degrees/sec~* Eccentric external rotation 60degrees/sec
Study: NCT06675981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Acupuncture
Description: Patients received 6 sessions of acupuncture (three sessions per week or every other day) for two consecutive weeks
Study: NCT06675981

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-acupuncture at real-acupoint
Description: The acupuncture simulation device will be used to perform acupuncture at the same acupoints as those of the real acupuncture group.
Study: NCT05577702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered as an intravenous infusion
Study: NCT06159647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will view neutral messages unrelated to the harms of alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Road injuries
Description: Participants will view messages about the risk of road injuries from alcohol consumption.
Study: NCT05577702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered as an intravenous infusion
Study: NCT06004388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Click Digital Therapeutic
Description: Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Click Digital Therapeutic
Description: Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
Study: NCT06447805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double Sequential Defibrillation (DSD)
Description: The second defibrillator will be applyed with electrodes placed in the A-P position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard defibrillation
Description: Standard defibrillation uning one defibrillator
Study: NCT06290206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT - BCT
Description: Bootcamp Translation (BCT), a method for engaging diverse stakeholders in a consensus-building process, has been used by this research team to actively develop and adapt study interventions. It uses an iterative, flexible schedule of face-to-face meetings combined with short, focused teleconferences. BCT emphasizes no wrong answers and no hierarchy of expertise. The process requires up to nine (9) hours of participant time over 3-6 months. Participants will be surveyed before and after the in-person session to assess learning outcomes and capture basic sociodemographic information.~The BCT process will define the format (mode and frequency) and content of messages to promote vaccine series completion. Auto and Auto-Plus intervention arms may use some of the same components (automated calls, live calls, text messages, emails, and mailings).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT - BCT
Description: Bootcamp Translation (BCT), a method for engaging diverse stakeholders in a consensus-building process, has been used by this research team to actively develop and adapt study interventions. It uses an iterative, flexible schedule of face-to-face meetings combined with short, focused teleconferences. BCT emphasizes no wrong answers and no hierarchy of expertise. The process requires up to nine (9) hours of participant time over 3-6 months. Participants will be surveyed before and after the in-person session to assess learning outcomes and capture basic sociodemographic information.~The BCT process will define the format (mode and frequency) and content of messages to promote vaccine series completion. Auto and Auto-Plus intervention arms may use some of the same components (automated calls, live calls, text messages, emails, and mailings).
Study: NCT06362967

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG
Description: For allogeneic haematopoietic stem cell transplantation patients with high titers of anti-HLA antibodies present in the body, a desensitisation regimen of immunosorbent or plasma exchange combined with rituximab and high-dose IVIG is used prior to transplantation.
Study: NCT05907707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma transcranial alternating current stimulation
Description: tACS (gamma frequency, 40Hz) during cognitive testing (about 40 minutes duration).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma transcranial alternating current stimulation
Description: tACS (gamma frequency, 40Hz) during cognitive testing (about 40 minutes duration).
Study: NCT04845776

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ANRC Essentials Plus
Description: a vitamin/mineral supplement designed for children and adults with autism
Study: NCT05907707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control transcranial alternating current stimulation
Description: tACS (control frequency, 21Hz) during cognitive testing (about 40 minutes duration).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control transcranial alternating current stimulation
Description: tACS (control frequency, 21Hz) during cognitive testing (about 40 minutes duration).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG headband
Description: At-home, ambulatory, single-channel EEG headband which records brain activity during sleep

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG headband
Description: At-home, ambulatory, single-channel EEG headband which records brain activity during sleep

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraphy wristband
Description: At-home, ambulatory, wrist-worn accelerometer which records levels of motor activity during the whole day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraphy wristband
Description: At-home, ambulatory, wrist-worn accelerometer which records levels of motor activity during the whole day